A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424-Reference-Cited by-同舟云学术

A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424

Published:2018-02-13 Issue:6 Volume:118 Page:770-776
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Woodcock Victoria K,Clive Sally,Wilson Richard H,Coyle Vicky M,Stratford Michael R L,Folkes Lisa K,Eastell Richard,Barton Claire,Jones Paul,Kazmi-Stokes Shamim,Turner Helen,Halford Sarah,Harris Adrian L,Middleton Mark R

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2017484.pdf

Reference35 articles.

1. Aleshin A, Finn RS (2010) SRC: a century of science brought to the clinic. Neoplasia 12 (8): 599–607.

2. Aligayer H, Boyd DD, Heiss MM, Abdalla EK, Curley SA, Gallick GE (2002) Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer 94 (2): 344–351.

3. Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Matveev VB, Efstathiou E, Oudard S, Morris MJ, Sizer B, Goebell PJ, Heidenreich A, de Bono JS, Begbie S, Hong JH, Richardet E, Gallardo E, Paliwal P, Durham S, Cheng S, Logothetis CJ (2013) Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol 14 (13): 1307–1316.

4. Baselga J, Cervantes A, Martinelli E, Chirivella I, Hoekman K, Hurwitz HI, Jodrell D, Hamberg P, Casado E, Elvin P, Swaisland A, Iacona R, Tabernero J (2010) Phase I safety, pharmacokinetics and inhibition of Src activity study of saracatinib in patients with solid tumors. Clin Cancer Res 16 (19): 4876–4883.

5. Bolen JB, Veillette A, Schwartz AM, DeSeau V, Rosen N (1987) Activation of pp60c-src protein kinase activity in human colon carcinoma. Proc Natl Acad Sci USA 84 (8): 2251–2255.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Harmonizing the craft of crafting clinically endorsed small-molecule BCR-ABL tyrosine kinase inhibitors for the treatment of hematological malignancies;European Journal of Pharmaceutical Sciences;2024-02

2. FYN: emerging biological roles and potential therapeutic targets in cancer;Journal of Translational Medicine;2023-02-05

3. Pathway profiling of a novel SRC inhibitor, AZD0424, in combination with MEK inhibitors for cancer treatment;Molecular Oncology;2021-12-18

4. Pathway profiling of a novel SRC inhibitor, AZD0424, in combination with MEK inhibitors;2021-08-29

5. Src family kinases, adaptor proteins and the actin cytoskeleton in epithelial-to-mesenchymal transition;Cell Communication and Signaling;2021-06-30